Tag - HBV

Feature

Spring Bank heading into data-rich 2020

Spring Bank Pharmaceuticals (NASDAQ:SBPH) will be reporting clinical data readouts throughout 2020 as it advances a portfolio of three drug candidates for the treatment of chronic hepatitis B virus (HBV) as well as...

November 12, 2019

Developments

Hepion Pharma doses first HBV patient in 28-day study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) has dosed the first hepatitis B virus (HBV) patient in a 28-day multiple ascending dose clinical trial of CRV431. The trial will assess the safety, tolerability and pharmacokinetics...

August 14, 2019

Tag - HBV

Spring Bank heading into data-rich 2020

Hepion Pharma doses first HBV patient in 28-day study of CRV431

General

More